188 related articles for article (PubMed ID: 32562096)
1. Pluripotent Stem Cell Modeling of Anticancer Therapy-Induced Cardiotoxicity.
Lyra-Leite DM; Burridge PW
Curr Cardiol Rep; 2020 Jun; 22(8):56. PubMed ID: 32562096
[TBL] [Abstract][Full Text] [Related]
2. High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells.
Sharma A; Burridge PW; McKeithan WL; Serrano R; Shukla P; Sayed N; Churko JM; Kitani T; Wu H; Holmström A; Matsa E; Zhang Y; Kumar A; Fan AC; Del Álamo JC; Wu SM; Moslehi JJ; Mercola M; Wu JC
Sci Transl Med; 2017 Feb; 9(377):. PubMed ID: 28202772
[TBL] [Abstract][Full Text] [Related]
3. Chronic Cardiotoxicity Assays Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs).
Narkar A; Willard JM; Blinova K
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328619
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin-induced cardiotoxicity is maturation dependent due to the shift from topoisomerase IIα to IIβ in human stem cell derived cardiomyocytes.
Cui N; Wu F; Lu WJ; Bai R; Ke B; Liu T; Li L; Lan F; Cui M
J Cell Mol Med; 2019 Jul; 23(7):4627-4639. PubMed ID: 31106979
[TBL] [Abstract][Full Text] [Related]
5. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity.
Liang P; Lan F; Lee AS; Gong T; Sanchez-Freire V; Wang Y; Diecke S; Sallam K; Knowles JW; Wang PJ; Nguyen PK; Bers DM; Robbins RC; Wu JC
Circulation; 2013 Apr; 127(16):1677-91. PubMed ID: 23519760
[TBL] [Abstract][Full Text] [Related]
6. Cardiotoxicity evaluation using human embryonic stem cells and induced pluripotent stem cell-derived cardiomyocytes.
Zhao Q; Wang X; Wang S; Song Z; Wang J; Ma J
Stem Cell Res Ther; 2017 Mar; 8(1):54. PubMed ID: 28279214
[TBL] [Abstract][Full Text] [Related]
7. Modeling Precision Cardio-Oncology: Using Human-Induced Pluripotent Stem Cells for Risk Stratification and Prevention.
Perry TR; Roberts ML; Sunkara B; Maddula R; McLeish T; Gomez J; Lucas J; Rayan D; Patel S; Liang M; Bosnjak ZJ; Brown SA
Curr Oncol Rep; 2021 May; 23(7):77. PubMed ID: 33937943
[TBL] [Abstract][Full Text] [Related]
8. Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity.
Yang X; Papoian T
J Appl Toxicol; 2018 Sep; 38(9):1166-1176. PubMed ID: 29484688
[TBL] [Abstract][Full Text] [Related]
9. Anthracycline-Induced Cardiotoxicity: Molecular Insights Obtained from Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs).
Bozza WP; Takeda K; Alterovitz WL; Chou CK; Shen RF; Zhang B
AAPS J; 2021 Mar; 23(2):44. PubMed ID: 33719006
[TBL] [Abstract][Full Text] [Related]
10. Cardiotoxicity and Heart Failure: Lessons from Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Anticancer Drugs.
Sachinidis A
Cells; 2020 Apr; 9(4):. PubMed ID: 32316481
[TBL] [Abstract][Full Text] [Related]
11. Protein-encapsulated doxorubicin reduces cardiotoxicity in hiPSC-cardiomyocytes and cardiac spheroids while maintaining anticancer efficacy.
Arzt M; Gao B; Mozneb M; Pohlman S; Cejas RB; Liu Q; Huang F; Yu C; Zhang Y; Fan X; Jenkins A; Giuliano AE; Burridge PW; Cui X; Sharma A
Stem Cell Reports; 2023 Oct; 18(10):1913-1924. PubMed ID: 37657447
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes.
Lee S; Lee HA; Choi SW; Kim SJ; Kim KS
Toxicol Appl Pharmacol; 2016 Apr; 296():42-53. PubMed ID: 26821276
[TBL] [Abstract][Full Text] [Related]
13. Cancer therapy-induced cardiomyopathy: can human induced pluripotent stem cell modelling help prevent it?
Stack JP; Moslehi J; Sayed N; Wu JC
Eur Heart J; 2019 Jun; 40(22):1764-1770. PubMed ID: 29377985
[TBL] [Abstract][Full Text] [Related]
14. Human Induced Pluripotent Stem Cell (hiPSC)-Derived Cells to Assess Drug Cardiotoxicity: Opportunities and Problems.
Magdy T; Schuldt AJT; Wu JC; Bernstein D; Burridge PW
Annu Rev Pharmacol Toxicol; 2018 Jan; 58():83-103. PubMed ID: 28992430
[TBL] [Abstract][Full Text] [Related]
15. Mechanobiology Assays with Applications in Cardiomyocyte Biology and Cardiotoxicity.
Blair CA; Pruitt BL
Adv Healthc Mater; 2020 Apr; 9(8):e1901656. PubMed ID: 32270928
[TBL] [Abstract][Full Text] [Related]
16. Development of In Vitro Drug-Induced Cardiotoxicity Assay by Using Three-Dimensional Cardiac Tissues Derived from Human Induced Pluripotent Stem Cells.
Takeda M; Miyagawa S; Fukushima S; Saito A; Ito E; Harada A; Matsuura R; Iseoka H; Sougawa N; Mochizuki-Oda N; Matsusaki M; Akashi M; Sawa Y
Tissue Eng Part C Methods; 2018 Jan; 24(1):56-67. PubMed ID: 28967302
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in pluripotent stem cell-derived cardiac organoids and heart-on-chip applications for studying anti-cancer drug-induced cardiotoxicity.
Liu S; Fang C; Zhong C; Li J; Xiao Q
Cell Biol Toxicol; 2023 Dec; 39(6):2527-2549. PubMed ID: 37889357
[TBL] [Abstract][Full Text] [Related]
18. Automated image analysis system for studying cardiotoxicity in human pluripotent stem cell-Derived cardiomyocytes.
Cao L; der Meer ADV; Verbeek FJ; Passier R
BMC Bioinformatics; 2020 May; 21(1):187. PubMed ID: 32408861
[TBL] [Abstract][Full Text] [Related]
19. Use of human induced pluripotent stem cell-derived cardiomyocytes to assess drug cardiotoxicity.
Sharma A; McKeithan WL; Serrano R; Kitani T; Burridge PW; Del Álamo JC; Mercola M; Wu JC
Nat Protoc; 2018 Dec; 13(12):3018-3041. PubMed ID: 30413796
[TBL] [Abstract][Full Text] [Related]
20. Integrating nonlinear analysis and machine learning for human induced pluripotent stem cell-based drug cardiotoxicity testing.
Kowalczewski A; Sakolish C; Hoang P; Liu X; Jacquir S; Rusyn I; Ma Z
J Tissue Eng Regen Med; 2022 Aug; 16(8):732-743. PubMed ID: 35621199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
